TITLE:
PUFA Augmentation in Treatment of Major Depression

CONDITION:
Major Depression

INTERVENTION:
Polyunsaturated Fatty Acids (PUFA)

SUMMARY:

      The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed
      up response to antidepressant therapy with Celexa (Citalopram) in people suffering from
      Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50%
      placebo EPA.
    

DETAILED DESCRIPTION:

      As per brief summary
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  Meet DSM-IV criteria for current major depression, and have a HAM-D (21 item) score
             of > 17

          -  Male or female who, if of child-bearing potential, agrees to use effective
             contraception including the regular use of contraceptive pills, intra-uterine
             devices, barrier methods or abstinence

          -  Age between 18 and 65

          -  Capable of giving informed consent

        Exclusion Criteria:

          -  Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder,
             schizotypal disorder, psychotic depression or bipolar disorders

          -  Current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or
             dependence within the previous 6 months

          -  Unstable medical or neurological conditions that are likely to interfere with the
             treatment of depression

          -  History of allergy to citalopram or ProEPA, finfish or shellfish

          -  History of failure of response to citalopram, as documented by an adequate trial of
             the medication [defined as having been treated with the medication at a dose level
             typically regarded as adequate (i.e., 40 mg of citalopram per day) for at least 6
             weeks]

          -  History of seizure disorder

          -  Pregnancy

          -  Currently on psychotropic medications including antidepressants or neuroleptics

          -  Active suicidal ideation or other safety issues determined by the clinician to not be
             suitable for inclusion in the study

          -  Exposure to treatment with fluoxetine or MAOIs in the previous two months

          -  Patients on anticoagulant therapy

          -  Patients with a dietary intake of > 3.0g total omega-3 PUFA/day at baseline
      
